Karyopharm Therapeutics (KPTI) was able to obtain FDA accelerated approval for its drug selinexor (to be marketed as Xpovio) for penta-refractory Multiple Myeloma ((MM)). This approval is good news for the biotech as it sets out to eventually obtain other regulatory approvals in MM and in other cancer indications with an unmet medical need. There is also a catalyst in which the biotech could receive European approval for selinexor in the same indication. With the pipeline the company has and which now has a proven ability to obtain FDA approval, things will only